Cargando…

Genotoxicity assessment of 4-methylimidazole: regulatory perspectives

4-Methylimidazole (4-MI) is formed as a result of the Maillard reaction process, and therefore is found in many foods and beverages. It is also found in soft drinks (i.e., cola) as a by-product in the production of some caramel colors. NTP bioassays revealed clear evidence of lung carcinogenicity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Takeshi, Uneyama, Chikako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088675/
https://www.ncbi.nlm.nih.gov/pubmed/27822321
http://dx.doi.org/10.1186/s41021-016-0050-z
_version_ 1782464144206725120
author Morita, Takeshi
Uneyama, Chikako
author_facet Morita, Takeshi
Uneyama, Chikako
author_sort Morita, Takeshi
collection PubMed
description 4-Methylimidazole (4-MI) is formed as a result of the Maillard reaction process, and therefore is found in many foods and beverages. It is also found in soft drinks (i.e., cola) as a by-product in the production of some caramel colors. NTP bioassays revealed clear evidence of lung carcinogenicity of 4-MI in male and female mice, but not in rats and then IARC classified 4-MI as group 2B carcinogen. Genotoxicity studies with 4-MI were negative in the Ames tests and in the erythrocyte micronucleus tests with mice or rats. US California EPA (CEPA) evaluated the testing has not been adequately comprehensive to rule out a genotoxic mode of action; as target tissue of the carcinogenicity of 4-MI was lung, the lung should be used as a source tissue for in vitro metabolic activation system. Thus, CEPA defined the No Significant Risk Level (NSRL) for 10(−5) lifetime risk level of cancer by 4-MI as 29 μg/day based on the non-threshold approach. As higher levels of 4-MI than the NSRL were identified in some kinds of cola, health concerns of 4-MI were drawn the attention. On the other hand, other regulatory bodies (e.g., European Food Safety Authority, EFSA) showed no concerns of 4-MI from the use of caramel colors in food. EFSA evaluated 4-MI is not genotoxic, so, non-observed adverse effect level of 4-MI was considered to be 80 mg/kg/day. In this paper, genotoxic assessments of 4-MI in different regulatory bodies are presented and the risk evaluation of 4-MI is discussed based on new genotoxicity data.
format Online
Article
Text
id pubmed-5088675
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50886752016-11-07 Genotoxicity assessment of 4-methylimidazole: regulatory perspectives Morita, Takeshi Uneyama, Chikako Genes Environ Commentary 4-Methylimidazole (4-MI) is formed as a result of the Maillard reaction process, and therefore is found in many foods and beverages. It is also found in soft drinks (i.e., cola) as a by-product in the production of some caramel colors. NTP bioassays revealed clear evidence of lung carcinogenicity of 4-MI in male and female mice, but not in rats and then IARC classified 4-MI as group 2B carcinogen. Genotoxicity studies with 4-MI were negative in the Ames tests and in the erythrocyte micronucleus tests with mice or rats. US California EPA (CEPA) evaluated the testing has not been adequately comprehensive to rule out a genotoxic mode of action; as target tissue of the carcinogenicity of 4-MI was lung, the lung should be used as a source tissue for in vitro metabolic activation system. Thus, CEPA defined the No Significant Risk Level (NSRL) for 10(−5) lifetime risk level of cancer by 4-MI as 29 μg/day based on the non-threshold approach. As higher levels of 4-MI than the NSRL were identified in some kinds of cola, health concerns of 4-MI were drawn the attention. On the other hand, other regulatory bodies (e.g., European Food Safety Authority, EFSA) showed no concerns of 4-MI from the use of caramel colors in food. EFSA evaluated 4-MI is not genotoxic, so, non-observed adverse effect level of 4-MI was considered to be 80 mg/kg/day. In this paper, genotoxic assessments of 4-MI in different regulatory bodies are presented and the risk evaluation of 4-MI is discussed based on new genotoxicity data. BioMed Central 2016-11-01 /pmc/articles/PMC5088675/ /pubmed/27822321 http://dx.doi.org/10.1186/s41021-016-0050-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Morita, Takeshi
Uneyama, Chikako
Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title_full Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title_fullStr Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title_full_unstemmed Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title_short Genotoxicity assessment of 4-methylimidazole: regulatory perspectives
title_sort genotoxicity assessment of 4-methylimidazole: regulatory perspectives
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088675/
https://www.ncbi.nlm.nih.gov/pubmed/27822321
http://dx.doi.org/10.1186/s41021-016-0050-z
work_keys_str_mv AT moritatakeshi genotoxicityassessmentof4methylimidazoleregulatoryperspectives
AT uneyamachikako genotoxicityassessmentof4methylimidazoleregulatoryperspectives